1. Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors
   Chun-Ta Huang et al, 2023, BMC Cancer CrossRef
2. Concordance of changes in the extracellular DNA of blood plasma and DNA of tumor tissue using the example of EGFR gene mutations in patients with non-small cell lung cancer
   A. A. Gneusheva et al, 2018, Laboratornaya sluzhba CrossRef
3. The Value of Liquid Biopsies for Guiding Therapy Decisions in Non-small Cell Lung Cancer
   Jatta Saarenheimo et al, 2019, Frontiers in Oncology CrossRef
4. Longitudinal monitoring of circulating tumour DNA improves prognostication and relapse detection in gastroesophageal adenocarcinoma
   Mark R. Openshaw et al, 2020, British Journal of Cancer CrossRef
5. Liquid biopsy in NSCLC: a new challenge in radiation therapy
   Annarita Perillo et al, 2021, Exploration of Targeted Anti-tumor Therapy CrossRef
6. Monitoring epidermal growth factor receptor C797S mutation in Japanese non–small cell lung cancer patients with serial cell‐free DNA evaluation using digital droplet PCR
   Ryo Ariyasu et al, 2021, Cancer Science CrossRef
7. Prognostic and predictive role of liquid biopsy in lung cancer patients
   Tuncay Goksel et al, 2024, Frontiers in Oncology CrossRef
8. The clinicopathological features and possible physiological mechanisms of only the EGFR-T790M primary mutation in patients with lung adenocarcinoma
   Ping Zhao et al, 2024, Pathology - Research and Practice CrossRef
9. Fully automated, on-site isolation of cfDNA from whole blood for cancer therapy monitoring
   Chi-Ju Kim et al, 2018, Lab on a Chip CrossRef
10. Diagnostic and prognostic impact of cell-free DNA in human cancers: Systematic review
    Klara Cervena et al, 2019, Mutation Research/Reviews in Mutation Research CrossRef
11. EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-Mutated NSCLC: A Prospective, Randomized, Exploratory Study
    Weiguang Gu et al, 2023, Cancer Research and Treatment CrossRef
12. LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology
    Pilar Garrido et al, 2021, Cancer Medicine CrossRef
13. Biomarkers of Osimertinib Response in Patients with Refractory, EGFR-T790M–positive Non–Small Cell Lung Cancer and Central Nervous System Metastases: The APOLLO Study
    Ligang Xing et al, 2020, Clinical Cancer Research CrossRef
14. Predictive impact of low-frequency pretreatment T790M mutation in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors
    Yoshiya Matsumoto et al, 2020, Lung Cancer CrossRef
15. Current and Emerging Applications of Droplet Digital PCR in Oncology: An Updated Review
    Susana Olmedillas-López et al, 2022, Molecular Diagnosis & Therapy CrossRef
16. A case report of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR -tyrosine kinase inhibitors with T790M mutation and epithelial-to-mesenchymal transition
    Nana Zhang et al, 2017, Respiratory Medicine Case Reports CrossRef
17. A multiple detection method for distinguishing gene mutations based on melting curves of extended quenching probes
    Wang Jianping et al, 2022, Heliyon CrossRef
18. Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings
    R Donald Harvey et al, 2020, Journal of Oncology Pharmacy Practice CrossRef